**CURRICULUM VITAE/个人简历**

***Stanislaw R. Burzynski, M.D., Ph.D. /斯坦尼斯洛·博金斯基***

**ACADEMIC TRAINING, CERTIFICATION AND LICENSURE**

**学术培训、认证及许可执照**

Texas State Board of Medical Examiners

德州州立委员会医疗考官

License to Practice Medicine, 1973

行医执照，1973年

Baylor College of Medicine, Houston, Texas

德克萨斯州休斯顿贝勒医学院

ECFMG Certificate, 1971

美国外国医学院校毕业生教育委员会认证，1971年

Medical Academy, Lublin, Poland

波兰卢布林医学研究院,

M.D. with Distinction, 1967

优秀医学博士，1967年

Ph.D. (Biochemistry), 1968

生物化学博士，1968年

**POSITIONS HELD**

**所获头衔**

President, Burzynski Research Institute Inc.

博金斯基研究所有限公司主席

Houston, TX, 1977 to present

德州休斯顿，1977年至今

Assistant Professor, Baylor College of Medicine

贝勒医学院副教授

Houston, Texas, 1972-1977

德州休斯顿1972-1977

Research Associate, Baylor College of Medicine

贝勒医学院副研究员

Houstn, Texas, 1970-1972

德州休斯顿1970-1972

Intern and Resident, Medical Academy, Internship in the Departments of Surgery, Internal Medicine, Pediatrics, Obstetrics and Gynecology, and Residency in the Department of Internal Medicine Lublin, Poland, 1967-1970

实习与住院医师，医学院外科、内科、儿科、妇产科实习医师，内科住院医师，波兰卢布林，1967-1970

Teaching Assistant, Medical Academy, Department of General Chemistry

医学院普通化学系助教

Lublin, Poland, 1962-1967

波兰卢布林，1962-1967

Research Worker, Medical Academy, Department of General Chemistry

医学院普通化学系研究员

Lublin, Poland, 1961-1962

波兰卢布林，1961-1962

**SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS**

科学与专业会员资格

American Academy of Anti-Aging Medicine

美国抗衰老医学科学院

American Academy of Medical Ethics.

美国医学伦理学会

American Association for Advancement of Science

美国科学进步协会

American Association for Cancer Research

美国癌症研究协会

American Association of Pharmaceutical Scientists

美国药学科学家协会

American Chemical Society

美国化学协会

American Diabetes Association

美国糖尿病协会

American Medical Association

美国医学会

European Association for Neuro-Oncology

欧洲神经肿瘤学协会

Harris County Medical Society

哈里斯郡医学会

International Union of Pure and Applied Chemistry

国际理论与应用化学联盟

New York Academy of Sciences

纽约科学院

Parenteral Drug Association

静脉药物协会

Society for Neuro-Oncology

神经肿瘤学协会

Society for Neuroscience

神经科学学会

Texas Medical Association

德克萨斯州医学协会

The Royal Society of Medicine (U.K.)

英国皇家医学协会

The Society of Sigma Xi

美国西格玛赛科学研究协会

World Medical Association

世界医学协会

World Society of Anti-Aging Medicine

世界抗衰老医学会

**RESEARCH SUPPORT**

**研究支持**

National Cancer Institute Grantee, 1974-1977

1974-1977年， 美国国立癌症研究所受助人

Baylor College of Medicine Grantee, 1976

1976年，美国贝勒医学院受助人

West Foundation Grantee, 1975

1975年，美国西部基金受助人

Medical Academy (Lublin, Poland) Grantee, 1962-1967

1962-1967年，波兰卢布林医学会受助人

Stanislaw R. Burzynski, M.D., Ph.D. – Page 2 of 43

**HONORS AND AWARDS**

**荣誉与获奖记录**

The Linus Pauling Award, October, 2008, ACAM

莱纳斯·鲍林奖，2008年，美国医学促进协会

The Linus Pauling Award, February, 2008, Orthomolecular Health-Medicine

莱纳斯·鲍林奖，2008年，分子矫正医学

The Order of Merit of the President of Poland – Officer’s Cross, October, 2004

波兰总统功绩勋章“军官十字勋章”，2004年十月，

Decoration of Polish Medical Association, November, 2001

波兰医学协会奖章，2001年十一月

The Order of Saint Brigida – Grand Cross with Star, November, 2001

圣布里奇达大十字星勋章，2001年十一月

The Order of Saint Stanislas – Grand Cross with Star, November, 2000

圣圣斯坦尼斯劳斯大十字星勋章，2001年十一月

The Order of Reconciliation – Noember, 2000

和谐勋章，2000年十一月

The Cross Virtus Nobilitat, June, 1999

“贤德使高尚”大十字勋章，1999年六月

The Wisdom Award of Honor, December, 1998

智慧奖荣誉奖章，1998年十二月

The Medal of the President of City of Lublin, Poland, December, 1998

波兰卢布林市总统奖章，1998年十二月

The Order of Saint Stanislas- Commander’s Cross with Star, December, 1997

圣圣斯坦尼斯劳斯统帅十字星勋章，1997年十二月

The Lady Liberty Award, July, 1997

自由女神奖，1997年7月

The Gold Medal from the American Institute of Polish Culture for outstanding achievements in the field of medicine and discovery of anti-cancer drugs antineoplastons, Miami, FL, February, 1997

美国波兰文化研究所颁发的医学领域与抗衰老药物抗瘤酮发明杰出贡献金质奖章，佛罗里达州迈阿密市，1997年2月

The Medal “Heart for Hearts” for saving human lives, Lublin, Poland, August, 1997

“全心全意”救死扶伤奖章，波兰卢布林市，1997年八月

The Memorial Medal of Zamoyski’s Lyceum in appreciation of outstanding contribution to increase scientific ranking of the school, Lublin, Poland, November, 1997

扎姆耶斯基学院纪念奖章，以奖励为推进学院的科学排名做出杰出贡献，波兰卢布林市，1997年十一月

The Heritage Award by Polish American Congress in recognition of extraordinary achievement in the research, treatment, and prevention of cancer, Chicago, IL, October, 1993.

波兰裔美国人大会传承奖章，以奖励在癌症研究、治疗以及预防方面的非凡成就，芝加哥市，1993年十月

Special Medal from the Polish government’s Institute for Drug Research and Control for achievement in the field of cancer research, Bialvstok, Poland, September, 1989

波兰政府药物研究与控制探究所特别奖，以奖励癌症研究领域的成果，波兰比亚韦斯托克市，1989年九月

Honorable Membership in the Academia del Medeterraneo, Rome, Italy, 1984

意大利罗马地中海学会荣誉会员，1984年

Recipient of commendation for Dedicated Service and for Personal Contribution made in the Advancement of Medical Education, Research and Health Care, Baylor College of Medicine, Houston, TX, April, 1977

贝勒医学院受表彰人，以表彰在医学教育、研究与医疗保健方面的进步热忱服务与个人贡献，德克萨斯州休斯敦市，1977年四月

Recipient of Medical Doctor Diploma with Distinction, Medical Academy, Lublin, Poland, 1967

波兰卢布林医学科学院优秀医学博士学历受表彰人，1967年

Co-winner of the prize for best paper presented at the 7th Conference of Polish Medical Student Research

Societies, Poznan, Poland, 1966.

第7届波兰医科学生研究学会大会最佳论文奖获奖人之一，波兰波兹南市，1966年

The Hereditary Title of Count

世袭伯爵头衔

**HONORABLE BIOGRAPHY 荣耀事迹**

Biography published in Marquis, Who’s Who in the World, 8th through 26th editions

个人简介刊载于《马奎斯世界名人录》第8版

Biography published in Marquis, Who’s Who in America, 51th through 63rd editions

个人简介刊载于《马奎斯美国名人录》第51版

Biography published in Marquis, Who’s Who in Science and Engineering, 2th through 6th editions

个人简介刊载于《马奎斯理工学科名人录》第2版

Biography published in Marquis, Who’s Who in Medicine and Healthcare, 1st through 6th editions

个人简介刊载于《马奎斯医学健康名人录》第1版

Biography published in Marquis, Who’s Who in Emerging Leaders in America, 1st edition

个人简介刊载于《马奎斯美国新兴行业领袖名人录》第1版

Biography published in Marquis, Who’s Who Frontiers of Science and Technology, 2nd edition

个人简介刊载于《马奎斯科技前沿名人录》第2版

Biography published in American Men and Women of Science, 13th Edition, Jacques Catell Press

个人简介刊载于《美国科学名人录》第13版，雅克·卡特尔出版社

**CHAIRMAN OF SCIENTIFIC SESSIONS AT INTERNATIONAL MEETINGS在国际会议中主持科学报告会经历**

Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM), Dubai, UAE, 2008

迪拜抗衰老与医学美学大会（DCAAAM），阿联酋迪拜，2008年

1st Anti-Aging International Symposium and Exposition, Tokyo, Japan, 2006

第一届抗衰老国际研讨与博览会，日本东京，2006年

International Conference in Integrative Medicine, Seattle, Washington, U.S.A, 1999

国际整合医学大会，美国华盛顿州西雅图市，1999年

Comprehensive Cancer Care I Conference, Washington, D.C., U.S.A., 1998

第一届综合肿瘤学大会，美国华盛顿特区，1998年

18th International Congress of Chemotherapy, Stockholm, Sweden, 1993

第18届国际化学疗法大会，瑞典斯德哥尔摩，1993年

17th International Congress of Chemotherapy, Berlin, Germany, 1991

第17届国际化学疗法大会，德国柏林，1991年

9th International Symposium on Future Trends in Chemotherapy, Geneva, Switzerland, 1990

第9届国际化学疗法未来趋势研讨会，瑞士日内瓦，1990年

10th Congress of the Polish Pharmacological Society, Bialystok, Poland, 1989

第10届波兰药理学协会大会，波兰比亚韦斯托克，1989年

8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Italy, 1988

第8届国际化学疗法未来趋势研讨会，意大利蒂雷尼亚，1988年

10th International Congress of Pharmacology, Sydney, Australia, 1987

第10届国际药理学大会，澳大利亚悉尼，1987年

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 3 of 43

**INVITED LECTURES** (given since 1988)

**受邀演讲（从1988年起）**

“Genomic and Epigenomic Principles of Cancer Treatment.” Keynote Speaker. Presented at the “10th

Scientific Meeting of the Japanese Society of Anti-Aging Medicine,” Kyoto, Japan, June 12,

2010.

第十届日本抗衰老医学会科学会议“癌症治疗的基因组学和基因表现学原理”主讲人，日本东京，2010年6月12日

“Genomic and Epigenomic Principles of Cancer Treatment.” Presented for 50 doctors at Keiko University, Tokyo, Japan, June 9, 2010.

庆应义塾大学“癌症治疗的基因组学和基因表现学原理”，日本东京，2010年6月9日

“Genomic and Epigenomic Principles of Cancer Treatment.” Presented for 10-20 doctors at Tokai

University, Tokyo, Japan, June 8, 2010.

东海大学“癌症治疗的基因组学和基因表现学原理”，日本东京，2010年6月9日

“Antineoplastons.” Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

为日本抗瘤酮研究小组作“抗瘤酮”演讲，日本东京，2009年5月13日

“Mechanisms of Anti-Tumor Activity in Synthetic Antineoplastons.” Presented for Antineoplastons

Study Group of Japan, Tokyo, Japan, May 13, 2009.

为日本抗瘤酮研究小组作“人造抗瘤酮的抑肿瘤活性机制”演讲，日本东京，2009年5月13日

“Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials.” Presented at the “Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM),” Dubai, UAE, 2008

“老化中基因静默原理的实际应用——动物与人类临床试验中的生命延长”，迪拜抗衰老与医学美学大会（DCAAAM），阿联酋迪拜，2008年

“Antineoplastons and Targeted Gene Therapy.” Presented at the “ACAM Las Vegas,” Las Vegas, Nevada, October 15-19, 2008

“抗瘤酮与基因靶向疗法”，美国医学促进会，内华达州拉斯维加斯市，2008年10月15-19日

“Genome, Epigenome and Aging.” Presented at the “First Annual Iberian Congress on Anti-Aging

Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“基因表象学与老化”，首届伊比利亚抗衰老医学与生物技术大会，葡萄牙埃斯托里尔，2008年5月29-31日

“Personalized Cancer Treatment in Genomics Era.” Presented at the “First Annual Iberian Congress on

Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“基因时代的个性化癌症治疗”，首届伊比利亚抗衰老医学与生物技术大会，葡萄牙埃斯托里尔，2008年5月29-31日

“Anti-Aging Peptides – A New Frontier in Healing.” Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“抗衰老多肽——康复新领域”2008年调整分子健康医学大会，旧金山，2008年2月

“Antineoplaston Peptides in Treating Cancer.” Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“癌症治疗中的抗肿瘤多肽” 2008年调整分子健康医学大会，旧金山，2008年2月

“Personalized Cancer Treatment.” Presented at the “2007 Total Health and Recovery Expo” in The

Woodlands, Texas, October 20, 2007

“个性化癌症治疗”，2007全面健康与康复博览会，德克萨斯州，2007年10月20日

“Cancer Treatment in Genomics Era.” Hosted by the Lions HealthFirst Foundation, at the Hilton in Las

Vegas, Nevada, September 15, 2007

“基因时代的个性化癌症治疗”，

“The Genetic Solution for Anti-Aging.” Presented at the “Healthy Directions Conference,” hosted by Dr.

Julian Whitaker at the Marriott Westchase in Houston, Texas, January 6, 2007

“The Genetic Solution for Anti-Aging.” Presented at 11th Cruising for Health and Wealth, January 2006 “New Cancer Treatments and Anti-Aging Regimens.” Presented at the “Polish Club of Leisure World,”

in Laguna Woods, California, March 13, 2005

“Mechanizmy I profilaktyka genetycznego starzenia (Mechanisms and Prevention of Genetic Aging).” Presented at the “Ogolnoeuropejska Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Neurologicznego,” in Lublin, Poland, September (wrzesień) 22-25, 2004

“Regulation of Gene Expression in Cancer and Aging.” Presented at “Innovations in

Complementary/Integrative Healthcare,” in Phoenix, Arizona, September 5-7, 2003 “Treatment of Cancer with Antineoplastons: Effect on Genes and Protein Metabolism.”

Presented at the “12th Annual Scientific Symposium,” in Orlando, Florida, August 27-31, 2003

“Gene Silencing in Cancer and Aging”. Presented at Graduation Ceremony: Ultrasound Diagnostic

School, November 15, 2002

“Antineoplaston Treatment of Cancer – Results of American and Japanese Clinical Trials.” Presented at

ABEIM – A Cancer Symposium, Fort Worth, Texas, 2002

“Antineoplaston Cancer Treatment – Theory and Results”; “Cancer and Aging – The Connection”; “Controlling the Key Aging Process of Methylation and Acetylation with the New Category of Anti-Aging Compounds and Antineoplastons.” Presented at the 6th International Symposium on Anti-Aging Medicine, Costa Rica, Los Suenos, August 23-24, 2002

“Treatment and Prevention of Cancer with Antineoplastons,” Presented in Santiago, Chile, July 3, 2002 “Antineoplastons –Theory and Treatment,” Presented at Seminar for Physicians: Sanoviv, Baja

California, June 13, 2002

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 4 of 43

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1.” Presented at Hyman-Newman

Institute for Neurology and Neurosurgery, Beth Israel Hospital, New York, August 22, 2001 “Treatment of Brain Tumors with Antineoplastons A10 and AS2-1”, Presented at Therapeutic Good

Administration (TGA) of Australia, Canberra, Australia, July 17, 2001

“Antineoplastons.” Presented at Polish Medical Association, Warsaw, Poland, November 22, 2000. “Treatment of Cancer with Antineoplastons.” Presented at Symposium organized by People Against Cancer in Stuttgart and Munich, Germany, for General Audience, November, 1999

“Antineoplastons: A Breakthrough in Cancer Therapy.” Presented at Manila Doctors Hospital, Manila, The Philippines, November 9, 1998

“The New Breakthrough in Cancer.” Presented at Marian Cancer Foundation, Manila, The Philippines,

November 6, 1998

“Antineoplastons.” Presented at “Surviving Cancer.” Westminster Central Hall, London, U.K., November 15, 1997

“Antineoplastons: Theory and Clinical Trials.” Presented at Medical Academy, Lublin, Poland, November 7, 1997

“Biochemical Defense System.” Presented at Medical Academy, Lodz, Poland, July 24, 1992 “Treatment of AIDS and HIV Infection with Antineoplastons AS2-1”. Presented at Search Alliance, Los

Angeles, California, November 20, 1991

“Cancer, AIDS and the other Immune System”. Presented at Foundation for the Advancement of

Innovative Medicine, New York, NY, October 26, 1991

“Antineoplastons.” Presented at World Research Foundation Congress, Los Angeles, California, October 7, 1990

“Antineoplastons—New Methods of Cancer Treatment.” Presented at Polish Pharmacological Society,

Lublin, Poland, August 29, 1989

“Clinical Results of Antineoplaston Therapy.” Presented at Kurume University School of Medicine, Kurume, Japan, April 9, 1988

“Mechanism of Action of Antineoplaston A10 and Experimental Data.” Presented at Kurume University

School of Medicine, Kurume, Japan, April 8, 1988

“Isolation, Purification and Synthesis of Antineoplastons.” Presented at Kurume University School of

Medicine, Kurume, Japan, April 8, 1988

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 5 of 43

**BOOK CHAPTERS, MONOGRAPHS AND ARTICLES BY S.R. BURZYNSKI AND ASSOCIATES**

**博金斯基医生本人及合作之专书论文、专题论文与文章**

1. Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Neuro-Oncology 2010; 12(6):ii95.
2. Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Neuro-Oncology 2010; 12(6):ii87.
3. Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Neuro-Oncology 2009; 11:923.

4 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S.

Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma: Protocol BC-BT-11. Neuro-Oncology 2009; 11:951.

5 Burzynski, S.R. The coming pandemic of liver cancer: In search of genomic solutions. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI; 2009.

6 Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients

of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells.

Neuro-Oncology 2008; 10:1148.

7 Burzynski, S., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Neuro-Oncology 2008; 10:1067.

8 Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells. Neuro-Oncology 2008; 10:786.

9 Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Neuro-Oncology

2008; 10:821.

10 Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Neuro-Oncology 2008; 10:450.

11 Burzynski, S.R. The genes of life. Farmapress Publishers, 2008.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 6 of 43

12 Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI; 2009.

13 Burzynski, S.R. Genomic approach to cancer treatment. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume X; 2008; 37-

44.

14 Burzynski, S.R. Recent clinical trials in diffuse intrinsic brainstem glioma.

Cancer Therapy 2007; 5, 379-390.

15 Burzynski, S.R., Weaver, R., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma. Neuro-Oncology 2007; 9:536.

16 Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Neuro-Oncology 2007; 9:482.

17 Burzynski, S.R. The Genetic Solution for Anti-Aging. In: American Academy of

Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007; 63-70.

18 Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007; 71-78.

19 Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007; 79-88.

20 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Neuro- Oncology 2007; 9:206.

21 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (5). Genes and aging of the neurons. Geny a starzenie neuronow. Czasopismo Aptekarskie 2007; Nr 3 (159) 27-38.

22 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (4). Time factor in biology and medicine. Czynnik czasu w biologii i medycynie. Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36.

23 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (3). The medicine of aging population. Medycyna starzejacego sie spoleczenstwa. Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48.

24 Burzynski, S.R. Targeted Therapy for Brain Tumors. Columbus F, ed. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006; 77-111.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 7 of 43

25 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (2). Epigenome and gene silencing. Epigenom i wyciszanie genow. Czasopismo Aptekarskie 2006; Nr 12 (156) 29-36.

26 Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (1). The medicine of genome an epigenome. Medycyna genomu i epigenomu. Czasopismo Aptekarskie 2006; Nr 11 (155) 45-52.

27 Burzynski, S.R. Age Management Treatments Which Target Silenced Genes.

Redberry GW, ed. Gene Silencing: New Research. Nova Science Publishers, Inc. 2006.

28 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006; 10:466.

29 Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgopolov, V. Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report. Neuro-Oncology. 2006; 10:439.

30 Burzynski, S.R. Treatments for Astrocytic Tumors in Children: Current and

Emerging Strategies. Pediatric Drugs 2006; 8:167-178.

31 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma. Integrative Cancer Therapies 2006; 5(1):40-47.

32 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas. Neuro-Oncology.

2006; 10:346.

33 Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. In: American Academy of Anti-Aging Medicine. American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics; Volume VIII 2006.

34 Burzynski, S.R. Master Clock of Life (I). “Junk DNA.” and Promoters Regions

as Major Components of the Clock. American Academy of Anti-Aging Medicine

(A4M) Anti-Aging Therapeutics; Volume VIII 2006.

35 Burzynski, S. R. Gene silencing theory of aging: the clinical trial supporting the theory. Anti-Aging Therapeutics Vol VII, 2005; 39-46.

36 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Neuro-Oncology. 2005; 7:300.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 8 of 43

37 Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Neuro-Oncology. 2005; 7:299.

38 Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 AS2-1. Integrative Cancer Therapies 2005; 4(2): 168-177.

39 Burzynski, S.R. Aging: Gene silencing or gene activation? Med Hypoth. 2005;

64, 201-208.

40 Burzynski, S.R. Mechanizmy i profilaktyka genetycznego starzenia.

Mechanisms and prevention of genetic aging. Neurologia I Psychiatria 2004; 4:

1-8.

41 Burzynski, S.R., Ilkowska-Musial, E., Klimczak M.W., Musial, L.

Antineoplastons In Dairy Products. Journal of Applied Nutrition. 2004; 54; 1-8.

42 Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Neuro-Oncology. 2004; 6:387.

43 Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. Neuro-Oncology. 2004; 6:384.

44 Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V. Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP). Preliminary results of phase II studies. Neuro-Oncology. 2004; 6:428.

45 Burzynski, S.R., Weaver, R. Bestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. A preliminary report. Neuro-Oncology. 2004; 6:427.

46 Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integrative Cancer Therapies. 2004; 3: 257-261.

47 Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report. Drugs R&D 2004; 5 (6): 315-326.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 9 of 43

48 Burzynski, S.R. The Present State of Antineoplaston Research. Integrative

Cancer Therapies 2004; 3: 47-58.

49 Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M. Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma (Preliminary Report). Drugs in R&D 2003; 4: 91-

101.

50 Waldbillig R, Burzynski SR. Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87. Neuro-Oncology. 2003; 10: 309.

51 Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma. A preliminary report. Neuro-Oncology. 2003; 10: 358.

52 Burzynski, S.R. The Methylation Control of Gene Activation and Silencing Theory. The Basic Principles and Practice of Anti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician. Vincent C. Giampapa (Ed.) 2003; 33-4.

53 Burzynski, S.R., Maxwell L. Axler, Robert I. Lewy, Tomasz Janicki, Elwira Ilkowska-Musial, Anna Baranowska, M.Sc. Amino Acid Supplementation in Treatment of Cancer-Related Symptoms. Journal of Applied Nutrition 2003;

53:52-60.

54 Burzynski, S. R. Gene Silencing - A New Theory of Aging. Med Hypoth. 2003;

60: 578-583.

55 Burzynski, S.R. Antineoplaston Therapy. Chapter in Integrative Oncology - Conventional and Complementary Strategies. Urban & Fischer; (in press).

56 Burzynski, S.R. Antineoplastons. In: Clinician's Complete Reference To

Complementary/Alternative Medicine, Novey, D. W. (Ed.). Mosby 2000; 496-

507, St.Louis, USA.

57 Burzynski, S.R. The Best of Alternative Medicine. Townsend Letter for Doctors

2000; 200: 32.

58 Burzynski, S.R., Conde, A.B., Peters, A., Saling B., Ellithorpe, R., Daugherty, J.P., and Nacht C.H. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors. Clin. Drug Invest. 1999; 18: 1-10.

59 Burzynski, S.R. Efficacy of Antineoplastons A10 and AS2-1. Mayo Clin. Proc.

1999; 74: 641- 643.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 10 of 43

60 Burzynski, S.R. Antineoplastons in the treatment of malignant brain tumors.

Anti-Aging Medical Terapeutics, vol. 2. Klatz RM., Goldman R. (Ed), Health

Quest Publications 1998; 28-34, Marina del Rey, Ca, USA.

61 Burzynski, S.R. Antineoplastons, oncogenes and cancer. Anti-Aging Medical Therapeutics, vol.1. Klatz RM, Goldman R. (Ed), Health Quest Publication 1997; Marina del Rey, CA, USA.

62 Burzynski, S.R. Potential of antineoplastons in diseases of old age. Drugs & Aging. 1995; 7: 157-167.

63 Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.

Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells. Cancer

Letters 88 (1995); 88: 107-112.

64 Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z.

The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exptl Clin Res. 1995; 21: 153-156.

65 Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs Exptl Clin Res. 1994; 20: 161-167.

66 Burzynski, S.R. Immunosurveillance versus chemosurveillance. Post Nauk Med.

1993; 6: 260-262.

67 Burzynski, S.R. Antineoplastons, An Investigational Cancer Therapy. Townsend

Letter for Doctors 1993; 3, 150-153.

68 Burzynski, S.R. Novel differentiation inducers. Recent Advances in

Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

69 Liau, M.C., Liau, C.P., Burzynski, S.R. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Internat J Exptl Clin Chemother. 1992; 5: 9-17.

70 Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug induced DNA hypermethylation by antineoplaston components. Internat J Exptl Clin Chemother. 1992; 5: 19-27.

71 Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992: Munich, Germany.

72 Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of drug-induced DNA hypermethylation by antineoplastons. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 11 of 43

73 Burzynski, S.R, Kubove, E., Burzynski, B. Phase II clinical trials of antineoplastons A10 and AS2-1 infusions in astrocytoma. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

74 Lee, S.S., Burzynski, S.R. Antineoplaston A5: A growth inhibitor for cancerous cells and growth stimulator for normal cells. Internat J Exptl Clin Chemother.

1991; 4: 63-65.

75 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Internat J Tissue Reactions. 1990; 12 (suppl): 43-50.

76 Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5. Internat J Tissue Reactions. 1990;

12 (suppl): 27-36.

77 Lee, S.S., Burzynski, S.R. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5. Internat J Exptl Clin Chemother. 1990; 3: 125-128.

78 Lee, S.S., Burzynski, S.R. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5. Internat J Tissue Reactions.

1990; 12 (suppl): 37-42.

79 Liau, M.C., Ashraf, A.Q., Lee, S.S., Hendry, L.B., Burzynski, S.R. Riboflavin as a minor active anticancer component of antineoplaston A2 and A5. Internat J Tissue Reactions. 1990; 12: 19-26.

80 Liau, M.C., Lee, S.S., Burzynski, S.R. Separation of active anticancer

components of antineoplaston A2, A3, and A5. Internat J Tissue Reactions. 1990;

12 (suppl): 1-17.

81 Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exptl Clin Res. 1990;

16: 361-369.

82 Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Internat

J Exptl Clin Chemother. 1989; 2: 63-69.

83 Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Internat J Exptl Clin Chemother.

1989; 2: 187-199.

84 Hendry, L.B., Muldoon, T.G., Burzynski, S.R. Modeling studies suggest the modified dipeptide analog phenylacetylamino-2, 6-piperidinedione may interact with DNA. Adv Exptl Clin Chemother. 1988; 2: 11-13.

85 Burzynski, S.R. Antineoplastons: Basic research and clinical applications. Adv

Exptl Clin Chemother. 1988; 2: 1-9.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 12 of 43

86 Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Adv

Exptl Clin Chemother. 1988; 6: 1-7.

87 Liau, M.C., Lee, S.S, Burzynski, S.R. Differentiation inducing components of antineoplaston A5. Adv Exptl Clin Chemother. 1988; 6: 9-25.

88 Lee, S.S., Burzynski, S.R. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2. Adv Exptl Clin Chemother. 1988; 6: 27-31.

89 Burzynski, S.R. Treatment of bladder cancer with antineoplaston formulations.

Adv Exptl Clin Chemother. 1988. 2: 37-46.

90 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of oral formulation of antineoplaston AS2-1. Adv Exptl Clin Chemother. 1988; 2: 29-36.

91 Burzynski, S.R. Treatment of malignant brain tumors with antineoplastons. Adv

Exptl Clin Chemother. 1988; 6: 45-56.

92 Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats. Adv Exptl Clin Chemother. 1988; 6: 33-39.

93 Ashraf, A.Q., Burzynski, S.R. Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients. Adv Exptl Clin Chemother. 1988;

2: 19-28.

94 Lee, S.S., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 31-35.

95 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by antineoplaston A10 of benzo (a) pyrene-induced pulmonary neoplasia. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 51-55.

96 Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Chemosurveillance: A novel concept of the natural defense mechanism against cancer. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 71-76.

97 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 13-16.

98 Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 57-60.

99 Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F.

Stereochemical modeling studies of the interaction of antineoplaston A10 with

DNA. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 77-81.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 13 of 43

100 Burzynski, S.R., Kubove, E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up. Drugs Exptl Clin Res.

1987; 13 (suppl 1): 1-12.

101 Burzynski, S.R., Kubove, E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 17-29.

102 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exptl. Clin Res. 1987; 13 (suppl 1): 37-43.

103 Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exptl Clin Res. 1987; 13 (suppl 1):

61-70.

104 Ashraf, A.Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res. 1987; 13 (suppl 1): 45-50.

105 Burzynski, S.R., Mohabbat. M.O. Chronic animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res. 1986; 12 (suppl 1): 73-75.

106 Ashraf, A.Q., Liau, M.C., Mohabbat, M.O., Burzynski, S.R. Preclinical studies of antineoplaston A10 injections. Drugs Exptl Clin Res. 1986; 12 (suppl 1): 37-45.

107 Burzynski, S.R., Mohabbat, M.O., Lee, S.S. Preclinical studies of antineoplaston

AS2-1 and antineoplaston AS2-5. Drugs Exptl Clin Res. 1986; 12 (suppl 1): 11-

16.

108 Burzynski, S.R. Antineoplaston A3. Drugs of the Future 1986; 11: 551-552.

109 Burzynski, S.R. Antineoplastons - History of the research (I). Drugs Exptl Clin

Res. 1986; 12 (suppl 1): 1-9.

110 Burzynski, S.R. Antineoplaston AS2-5. Annual Drug Data Report. 1986; 8: 319.

111 Burzynski, S.R. Antineoplaston AS2-1. Annual Drug Data Report. 1986; 8: 320.

112 Burzynski, S.R., Khalid, M. Antineoplaston AS2-5. Drugs of the Future 1986;

11: 364-365.

113 Burzynski, S.R. Antineoplaston A10 injections. Annual Drug Data Report. 1986;

8: 597.

114 Burzynski, S.R. Antineoplaston A3. Annual Drug Data Report. 1986; 8: 412.

115 Burzynski, S.R. Antineoplaston A2. Annual Drug Data Report. 1986; 8: 504.

116 Burzynski, S.R., Khalid, M. Antineoplaston AS2-1. Drugs of the Future 1986;

11: 361-363.

117 Burzynski, S.R. Antineoplaston A2. Drugs of the Future 1986; 11: 549-550.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 14 of 43

118 Burzynski, S.R. Antineoplaston A5. Annual Drug Data Report. 1986; 8: 869.

119 Burzynski, S.R. Antineoplaston A5. Drugs of the Future 1986; 11: 824-825.

120 Burzynski, S.R. Synthetic antineoplastons and analogs. Drugs of the Future

1986; 11: 679-688.

121 Liau, M.C., Burzynski, S.R. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy. Drugs Exptl Clin Res. 1986; 12 (suppl

1): 77-86.

122 Lehner, A.F., Burzynski, S.R., Hendry, L.B. 3-phenylacetylamino-2, 6- piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. Drugs Exptl Clin Res. 1986; 12 (suppl 1): 57-72.

123 Burzynski, S.R., Kubove, E. Toxicology studies of antineoplaston A10 injections in cancer patients. Drugs Exptl Clin Res. 1986; 12 (suppl 1): 47-55.

124 Burzynski, S.R. Toxicology studies of antineoplaston AS2-5 injections in cancer patients. Drugs Exptl Clin Res. 1986; 12 (suppl 1): 17-24.

125 110 Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Toxicology studies of antineoplaston AS2-1 injections in cancer patients. Drugs Exptl Clin Res. 1986;

12 (suppl 1): 25-35.

126 Burzynski, S., Mohabbar. M., Lee, S. Preclinical studies of antineoplaston AS2-1 in mice with oral administration. Drugs Exptl Clin Res. 1986; 132.

127 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and acute animal toxicity studies of antineoplaston A2. Future Trends in Chemotherapy 1985; 6:

481-484.

128 Burzynski, S.R., Hai TT. Antineoplaston A10. Drugs of the Future 1985; 10:

103-105.

129 Burzynski, S.R. Phase I clinical studies of antineoplaston AS2-5 injections.

Recent Advances in Chemotherapy. Ishigami J. (Ed), University of Tokyo Press.

1985; Tokyo, Japan.

130 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. Future Trends in Chemotherapy 1985; 6: 485-493.

131 Burzynski, S.R., Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. Drugs Exptl Clin Res. 1984; 10: 113-118.

132 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res. 1984; 10: 607-610.

133 Burzynski, S.R. Antineoplaston A10. Annual Drug Data Report. 1984; 6: 124.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 15 of 43

134 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Human toxicology studies on oral formulation of antineoplaston A10. Drugs Exptl Clin Res. 1984; 10: 891-

909.

135 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. Drugs Exptl Clin Res.

1984; 10: 611-619.

136 Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F. Polypeptides that inhibit human breast cancer cell division. Cancer Biochem Biophys. 1979; 3: 93-96.

137 Burzynski, S.R. Antyneoplastony. Przeglad Lekarski. 1978; 6: 583-586.

138 Gross S, Galicka N, Grabarczyk M, Giannini M, Burzynski SR, Stolzmann Z.

Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells. Clin Chem. 1977; 23: 148-149.

139 Burzynski, S.R., Stolzmann, Z., Szopa, B., Stolzmann, E., Kaltenberg, O.P.

Antineoplaston A in cancer therapy (I). Physiol Chem Phys. 1977; 9: 485-500.

140 Burzynski, S.R. Antineoplastons: Biochemical defense against cancer. Physiol

Chem Phys. 1976; 8: 275-279.

141 Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A. Urinary peptides in muscular dystrophy. Physiol Chem Phys. 1976; 8: 161-166.

142 Burzynski, S.R. Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin). Anal Biochem. 1976; 70: 359-365.

143 Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H.

Biologically active peptides in human urine: III. Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells. Physiol Chem Phys. 1976; 8: 13-22.

144 Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z. Inhibition of the Growth of

HeLa Cells by the Peptide Isolated from Normal Human Urine. Fed Proc. 1976;

35: 623.

145 Burzynski. S.R. Quantitative analysis of amino acids and peptides in the femtomolar range. Anal Biochem. 1975; 65: 93-99.

146 Burzynski, S.R., Ungar, G. Brain Peptides Associated with Habituation to a

Sound Stimulus. Neuroscience Abstracts. 1975; 1: 329.

147 Ungar, G., Burzynski, S.R., Tate, D.L. Learning-induced Brain Peptides.

Peptides: Chemistry, structure and biology. Walter, R., Meienhofer, J. (Ed), Ann

Arbor Science; 1975; Ann Arbor, Michigan, USA.

148 Burzynski, S.R., Ungar, A.L., Lubanski, E. Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart. Physiol Chem Phys. 1974;

6: 457-468.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 16 of 43

149 Burzynski, S.R., Ungar, A.L., Lubanski, E. Effect of Urinary Peptides on Smooth

Muscle and Heart. Fed Proc. 1974; 33: 547.

150 Burzynski, S.R. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides. Physiol Chem Phys. 1973; 5: 437-447.

151 Burzynski, S.R., Georgiades, J. Effect of Urinary Peptides on DNA, RNA and

Protein Synthesis in Normal and Neoplastic Cells. Fed Proc. 1973; 32: 766.

152 Ungar, G., Burzynski, S.R. Isolation and Purification of a Habituation-inducing

Peptide from Trained Rat Brain. Fed Proc. 1973; 32: 367.

153 Burzynski, S., Czerniak, Z. A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum. Chem Anal. 1970; 15: 223-225.

154 Szajner-Milart, J., Burzynski, S.R., Paczos-Chadyma, E., Czerniak, Z. Free amino acids in serum of obese children. Endokr Pol. 1970; 21: 611-617.

155 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, I. Results obtained in various conditions using paper and thin-layer chromatography. Chem Anal. 1969; 13:

1221-1228.

156 Burzynski, S. Investigations on unknown ninhydrin-reacting substances in human blood serum I. Attempts at identification of three such substances. Experientia.

1969; 25: 490-491.

157 Burzynski, S. Bound amino acids in serum of patients with chronic renal insufficiency. Clin Chim Acta. 1969; 25: 231-237.

158 Czerniak, Z., Burzynski, S. Free amino acids in serum of patients with chronic renal insufficiency. Clin Chim Acta. 1969; 24: 367-372.

159 Burzynski, S., Czerniak, Z. A simple method for free and bound amino acid separation. Folia Soc Sci Lub. 1969/70; Sec. A-D 9/10 (suppl): 143-144.

160 Burzynski, S., Czerniak, Z. Quantitative determination of amino acids using photometry of negative printed chromatograms. Modification of the method and its application for amino acid analysis in blood serum. Chem Anal. 1969; 14:

667-671.

161 Czerniak, Z., Burzynski, S. Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents. Chem Anal. 1969; 14: 673-

676.

162 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer. Pol Arch Med Wewn. 1968; 40: 223-228.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 17 of 43

163 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms. Pol Arch Med Wewn. 1968; 41: 361-368.

164 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, II. Analysis of variance for four- crossed classification and Tukey confidence intervals. Chem Anal. 1968; 13:

1229-1238.

165 Burzynski, S. Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency. 1968; Lublin, Poland: 274 pp (doctoral dissertation).

166 Krzeczkowska, I., Burzynski, S. Czerniak Z. Quantitative determination of amino acids using photometry of negative printed chromatograms. Ann Univ MC Sklodowska 1966; 21: 125-134.

167 Krzeczkowska, I., Czerniak, Z., Burzynski, S. The application of the negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people. Ann Univ MC Sklodowska 1966; 21: 313-322.

168 Krzeczkowska, I., Burzynski, S., Czerniak, Z. Investigations on the possibility of the determination of mushroom species on the basis of the composition of their amino acids. Ann Univ MC Sklodowska 1965; 20: 221-229.

169 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Free and bound amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1965; 20: 303-312.

170 Krzeczkowska, I., Czerniak, Z., Burzynski, S. Bound amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1964; 19: 329-336.

171 Krzeczkowska, I., Burzynski, S., Czerniak, Z. Free amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1964; 19: 321-328.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 18 of 43

**SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES**

**博金斯基医生本人及合作者演讲报告摘要选列**

1 Burzynski, S.R, Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna,

Austria.

2 Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.

3 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S.

Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Protocol BC-BT-11. Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

4 Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

5 Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K.

Antineoplastons inhibit MCM complex in glioblastoma cells. Presented at the 3rd

Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the

6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

6 Burzynski, S.R. New research on molecular mechanisms and prevention of Alzheimer’s disease. Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; April

21-April 25, 2009; Orlando, Florida.

7 Burzynski, S. Life extension through application of chromatin remodeling agents.

Presented at the 7th Anti-Aging Medicine World Congress & Medispa; March 19- March 21, 2009; Monte-Carlo, Monaco.

8 Marquis, A., Kubove, E., Walczak, M., Burzynski, S. Hepatocellular carcinoma, recurrent after standard therapy, successfully treated with a combination of targeted therapies. Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 19 of 43

9 Weaver, R., De Leon, L., Burzynski, S. A complete response in a patient with inoperable adenocarcinoma of the head of the pancreas treated with a combination of gene-targeted therapies. Presented at the 20th International Congress on Anti- Cancer Treatment; February 3-February 6, 2009; Paris, France.

10 Burzynski, S.R. The Coming Pandemic of Liver Cancer. In Search of Genomic

Solutions. Presented at the 16th Annual World Congress of A4M, Winter 2008

Session; December 12-December 15, 2008; Las Vegas, Nevada.

11 Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Presented at the

13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-

November 23, 2008; Las Vegas, Nevada.

12 Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells. Presented at the 13th Annual Scientific Meeting of the Society for Neuro- Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

13 Burzynski, S.R., Patil, S., Ilkowska-Musial, E., Chittur, S., Gupta, V., Sarangi, R.

Pathway analysis of the effect of chromatin remodeling agent phenylbutyrate on

the brains of honeybees. Presented at Neuroscience 2008; November 15- November 19, 2008; Washington D.C.

14 Burzynski, S.R. Genomics in Cancer Treatment. Presented at Dubai Congress on

Anti-Aging and Aesthetic Medicine; November 7-November 9, 2008; Dubai.

15 Burzynski, S.R. Genetics of Longevity. Presented at Dubai Congress on Anti- Aging and Aesthetic Medicine; November 7-November 9, 2008; Dubai.

16 Burzynski, S.R. Antineoplastons and Targeted Gene Therapy. Presented at

ACAM Scientific Conference; October 15-October 19, 2008; Las Vegas, Nevada.

17 Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.

18 Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Presented at the European Association for NeuroOncology (EANO); September

12-September 14, 2008; Barcelona, Spain.

19 Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11- September 14, 2008; Düsseldorf, Germany.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 20 of 43

20 Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Presented at the 13th International Symposium on Pediatric Neuro-Oncology; June 29-July 2, 2008; Chicago,

Illinois.

21 Burzynski, S.R. Genome, Epigenome and Aging. Presented at the First Annual

Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May

29-31, 2008; Estoril, Portugal.

22 Burzynski, S.R. Personalized Cancer Treatment in Genomics Era. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.

23 Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animals and human clinical trials. Presented at the 16th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida.

24 Burzynski, S.R. Antineoplaston peptides in treating cancer. Presented at the

2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.

25 Burzynski, S.R. Anti-Aging peptides—a new frontier in healing. Presented at the

2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008;

San Francisco, California.

26 Burzynski, S.R. Genomic approach to cancer treatment. Presented at the 15th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada.

27 Burzynski, S.R. Genomics in Cancer Treatment. Presented at the 1st Annual

India Conference on Anti-Aging and Regenerative Medicine; November 16-18,

2007; Mumbai, India.

28 Burzynski, S.R. Epigenomic Approach to Anti-Aging. Presented at the 1st

Annual India Conference on Anti-Aging and Regenerative Medicine; November

16-18, 2007; Mumbai, India.

29 Burzynski, S.R., Weaver, R.A., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent, diffuse, intrinsic brainstem anaplastic astrocytoma. Presented at the Society for Neuro-Oncology

12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

30 Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Presented at the Society for Neuro- Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 21 of 43

31 Burzynski, S.R., Tempczyk-Russell, A., Ilkowska-Musial, E. Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory. Presented at Neuroscience 2007, the Society’s Annual Meeting; November 3-7,

2007; Sand Diego, California.

32 Burzynski, S.R. Epigenomic approach to anti-aging. Presented at: 4th Congresso

Internacional de Antienvelhecimento; October 26-27, 2007; Sao Paulo, Brazil.

33 Burzynski, S.R. Nutrition and ageing : Gene silencing or gene activation.

Presented at: 10th European Nutrition Conference; July 10-13, 2007; Paris, France.

34 Burzynski, S.R. La solution génétique contre le vieillissement. Presented at: Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo.

35 Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. Presented at: 14th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada.

36 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.J., Khan, M.I., Dolgopolov, V. Treatment of multicentric brainstem gliomas with Antineoplastons (ANP) A10 and AS2-1. Presented at the Society for Neuro- Oncology’s 11th Annual Meeting; November 16-19, 2006; Orlando, Florida.

37 Burzynski, S.R., Christensen, R., Ilkowska-Musial, E. Memory processing proteins have common amino acid sequences with Scotophobin. Presented at: Neuroscience 2006, the Society’s 36th annual meeting; October 14-18, 2006; Atlanta, Georgia.

38 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B., Jurida, G.F. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brainstem gliomas. Presented at: The European Association for Neuro Oncology: 7th Congress Vienna Hofburg Congress Center; September 14-17,

2006; Vienna, Austria.

39 Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons.

Presented at: 14th Annual International Congress on Anti-Aging Medicine; July

14-16, 2006; Chicago, Illinois.

40 Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 1st Anti- Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

41 Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (III) Aminocare Products and Aging of the Brain. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

42 Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (II) Aminocare Products and Skin Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 22 of 43

43 Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (I) Theory and Age-Management with Aminocare Products. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan

44 Burzynski, S.R. Gene Silencing Theory of Aging. Presented at: 1st Anti-Aging

International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

45 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Presented at:

12th International Symposium on Pediatric Neuro-Oncology; June 6-9, 2006;

Nara, Japan.

46 Burzynski, S.R. Chronobiology of Aging. Presented at: International Danube

Symposium for Neurological Sciences and Continuing Education; May 10-13,

2006; Kazimierz Dolny, Poland.

47 Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 14th International Congress on Anti-Aging Medicine; April 7-9, 2006; Orlando, Florida.

48 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Jurida, G.F.

Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in

patients with recurrent, diffuse intrinsic brain stem gliomas. Presented at the 17th International Congress on Anti-Cancer Treatment; January 30-February 2, 2006; Paris, France.

49 Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back.

Presented at: XIII International Congres on Anti-Aging Medicine; December 8-

12, 2005; Las Vegas, Nevada.

50 Burzynski, S.R. Master Clock of Life (I) "Junk DNA" and Promotors Region as Major Components of the Clock. Presented at: XIII International Congres of Anti-Aging Medicine; August 19-21, 2005; Chicago, Illinois.

51 Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.

52 Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 23 of 43

53 Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 (ANP) of high grade, recurrent and progressive brain stem glioma. Presented at the 16th International Congress on Anti-Cancer Treatment; February 1-4, 2005; Paris, France.

54 Burzynski, S.R. Antineoplastons. Presented at: The Cleveland Clinic Neuro- Oncology 2005: Current Concepts; January 29-31, 2005; Lake Buena Vista, FL, USA.

55 Burzynski, S.R., Jacquet, A., Moore, N., Musial, L. Gene silencing theory of aging: the clinical trial supporting the theory. Presented at: American Academy of Anti-Aging Medicine (A4M) Conference on Anti-Aging Medicine, December

3-6, 2004; Las Vegas, USA.

56 Burzynski, S.R., Weaver, R. Bestak. M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse

intrinsic brain stem glioma. Presented at: 9th Annual Meeting Society for Neuro- Oncology, November 18-21, 2004; Toronto, Canada.

57 Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgopolov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21,

2004; Toronto, Canada.

58 Burzynski, S.R., Janicki, T., Weaver, R., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V. Clinical application of body epigenetic system. Multi-targeted therapy for primary brain tumors. Presented at World Conference on Magic Bullets Celebrating Paul Ehrlich's 150th Birthday; September, 2004; Nurnberg, Germany.

59 Burzynski, S.R. The new generation of food supplements effecting gene expression. Presented at 2nd Congress Food, Nutrition and Health in Poland Intergrated with European Union; June 23-26, 2004; Warsaw, Poland.

60 Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Szymkowski, B., Jurida G., Khan, M., Dolgopolov, V. Treatment of Primitive Neuroectodermal Tumors (PNET) with Antineoplastons A10 and AS2-1 (ANP). Preliminary Results of Phase II Studies. Presented at 11th International Symposium on Pediatric Nuero- Oncology; June 13-16, 2004; Boston, MA.

61 Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J, Jurida G., Szymkowski, B., Khan, M., Dolgopolov, V. Phase II Studies of Antineoplastons A10 and AS2-

1 (ANP) in Children with Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System. A Preliminary Report. Presented at 11th International Symposium on Pediatric Neuro-Oncology; June 13-16, 2004; Boston, MA.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 24 of 43

62 Burzynski, S.R., Lewy, R.I., Axler, M., Janicki, T.J. Treatment of Malignant Mesothelioma (MM) with Sodium Phenylbutyrate. Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.

63 Waldbillig, R.J., Mrowczynski, E., Burzynski, S.R. Phenylacetic acid (PN) and Phenylacetylglutamine (PG): Mechanism of Uptake and changes in Epigenetic- Mechanisms Regulating Gene Expression. Presented at the 2nd Annual American Association for Cancer Research (AACR) International Conference; October 26-

30, 2003, Phoenix, AZ.

64 Burzynski, S.R. Interaction of antineoplastons with genome in cancer and aging.

Presented at: Annual Meeting of International Academy of Oral Medicine and

Toxicology; September 12-13, 2003, New Orleans, Louisiana.

65 Burzynski, S.R. Antineoplastons in: Cancer Treatment and Age Management Therapy. Presented at American Collage for Advancement in Medicine (ACAM); May 16, 2003, Washington, DC.

66 Burzynski, S.R. The State of Antineoplaston Research - Spring of 2003.

Presented at the 5th Annual Comprehensive Cancer Care Conference; April 11,

2003, Washington, DC.

67 Waldbillig, R.J., Burzynski, S.R. The application of chromatography to the pharmacokinetic study of Antineoplastons A10 and AS2-1. Presented at the 3rd International Symposium of Chromatography and Natural Products; June 12-15,

2002, Lublin, Poland.

68 Burzynski, S.R. Antineoplastons. Presented at 'Health-Trends 2000', The 2nd

International Conference; August 27-29, 1999, Copenhagen, Denmark.

69 Burzynski, S.R. Phase II Trial of Antineoplaston A10 and AS2-1 in Brain Stem

Glioma. Presented at International Conference on Integrative Medicine; May 1,

1999, Seattle, Washington, USA.

70 Czerwinski, A., Klimczak, M.W., Burzynski, S.R. Enancjoselektywna analiza skladnikow Antyneoplastonu A10 metoda HPLC. Presented at the XVII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego, September 1998, Krakow, Poland.

71 Burzynski, S.R. Gene Therapy with Antineoplastons. Presented at

Comprehensive Cancer Care; June, 1998, Washington, D.C., USA.

72 Burzynski, S.R. Antineoplastons in the Treatment of Malignant Brain Tumors.

Presented at 5th International Conference of Anti-Aging Medicine and Biomedical

Technology; December, 1997, Las Vegas, Nevada, USA.

73 Burzynski, S.R. New Concepts in Innovative Cancer Therapies. Presented at 4th

Annual Conference on Anti-Aging Medicine and Biomedical Technology; Dec.,

1996, Las Vegas, Nevada, USA.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 25 of 43

74 Burzynski, S.R. Antineoplastons Today. Presented at the First International Congress On Alternative & Complementary Medicine; May, 1995; Washington, DC, USA.

75 Soltysiak-Pawluczuk, D., Burzynski, S.R. Uptake Characteristics of Antineoplaston AS2-1 by Human Hepatoma Cells. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

76 Lee, S.S., Burzynski, S.R. Synergistic Inhibitory Effect of Antineoplaston A5 and Thymidine on the Growth of Human Cancer Cell Lines. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

77 Liau, M.C., Liau, C.P., Burzynski, S.R. Helper Inducers of Terminal Differentiation. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

78 Burzynski, S.R., Szymkowski, B., Kubove, E. Phase II Clinical Trials of Antineoplaston AS2-1 in Asymptomatic HIV Infection. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

79 Burzynski, S.R., Kubove, E., Szymkowski, B. Phase II Clinical Trials of

Antineoplaston A10 and AS2-1 Infusions in High Grade Glioma. Presented at the

18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.

80 Kleinrok, Z., Burzynski, S.R., Juszkiewicz, M., Chodkowska, A., Feldo, M. The Influence of Antineoplaston A5 on the Central Dopaminergic Structures. Presented at: 11th Congress of the Polish Pharmacological Society; September,

1992; Gdansk, Poland.

81 Burzynski, S.R., Kubove, E., Szymkowski, B., Burzynski, B. Phase II Clinical Trials of Novel Differentiation Inducer - Antineoplaston AS2-1 in AIDS and Asymptomatic HIV Infection. VIII International Conference on AIDS/III STD World Congress; July, 1992; Amsterdam, The Netherlands.

82 Burzynski, S.R. Differentiation Inducers-Possible Agents for Cancer Therapy in Pregnancy. Presented at the World Congress of Prenatal and Perinatal Psychology and Medicine; May, 1992; Krakow, Poland.

83 Burzynski, S.R., Kubove, E., Burzynski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in Astrocytoma. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

84 Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R. Prevention of Drug-Induced DNA Hypermethylation by Antineoplastons. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

85 Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 26 of 43

86 Liau, M.C., Lee, S.S., Liau, C.P., Burzynski, S.R. Efficient Methylation when Locked in Place Becomes a Major Problem of Cancer. Presented at the 82nd Annual Meeting of the American Association for Cancer Research, May, 1991, Houston, Texas, USA.

87 Burzynski, S.R. Antineoplastons. Presented at: The World Research Foundation

Congress, October 7, 1990, Los Angeles, CA, USA.

88 Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston AS2-1 Following Oral Administration in Rats. Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.

89 Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of Hormonally Refractory Cancer of the Prostate with Antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy, March, 1990, Geneva, Switzerland.

90 Liau, M.C., Lee, S.S., Burzynski, S.R. Abnormal Methylation Enzymes as Selective Targets of Cancer Therapy. Presented at the 42nd Annual Symposium on Fundamental Cancer Research, M.D. Anderson Hospital and Tumor Institute; October, 1989; Houston, Texas, USA.

91 Liau, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of Nucleic Acids: A Key to the Induction of Terminal Differentiation. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

92 Burzynski, S.R. Antineoplastons - New Way for Cancer Chemotherapy.

Presented at the 10th Congress of the Polish Pharmacological Society, September,

1989, Bialystok, Poland.

93 Liau, M.C., Lee, S.S., Burzynski, S.R. Role of Methylation Enzymes in Directing Phenotypic Changes. Presented at the 41st Annual Symposium on Fundamental Cancer Research. M.D. Anderson Hospital and Tumor Institute; October, 1988; Houston, Texas, USA.

94 Liau, M.C., Khalid, M., Burzynski, S.R. Differentiation Inducing Factors of Antineoplaston A5. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

95 Khalid, M., Burzynski, S.R. Phenylacetylglutamine Derivatives as Novel Chemotherapeutic Agents. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

96 Lee, S. S., Burzynski, S.R. Terminal Differentiation of HL-60 Human

Promyelocytic Leukemia Cells Induced by Antineoplaston A2. Presented at the

8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 27 of 43

97 Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Analysis of Antineoplaston A10 Injections Following Intravenous Administration in Rats. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

98 Burzynski, S.R. Treatment of Malignant Brain Tumors with Antineoplastons.

Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

99 Liau, M.C., Lee, S.S., Burzynski, S.R. Modulation of Tumor Methylation Complex Isozymes as a Decisive Factor in the Induction of Differentiation by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

100 Lee, S.S., Burzynski, S.R. Induction of Differentiation of HL-60 Human Promyelocytic Leukemic Cells by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November,

1987; Madrid, Spain.

101 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Protective Effect of

Antineoplaston A10 in Hepatocarcinogenesis Induced by Aflatoxin B 1. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

102 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston A3. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

103 Liau, M.C., Ashraf, A.Q., Burzynski, S.R. Active Anticancer Components of Antineoplaston Formulations. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

104 Ashraf, A.Q., Burzynski, S.R. Comparative Study of Antineoplaston A10 Levels in Plasma of Healthy People and Cancer Patients. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

105 Burzynski, S.R. Treatment of Bladder Cancer with Antineoplaston Formulations.

Presented at the 15th International Congress of Chemotherapy; July, 1987;

Istanbul, Turkey.

106 Burzynski, S.R. Antineoplastons: Basic Research and Clinical Applications.

Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

107 Burzynski, S.R. Modeling Studies Suggest the Modified Dipeptide Analog Phenylacetylamino-2, 6-piperidinedione May Interact with DNA. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 28 of 43

108 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston AS2-1. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.

109 Lee, S.S., Burzynski, S.R. A Unique Pattern of Growth Inhibition by Antineoplaston A5 on a T-Leukemia Cell Line. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.

110 Liau, M.C., Kampalath, B.N., Szopa, M., Burzynski, B., Burzynski, S.R. Chemo- surveillance: A Novel Concept on the Natural Defense Mechanism Against Cancer. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.

111 Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by Antineoplaston A10 on Benzo (1) pyrene Induced Pulmonary Neoplasia. Presented at the 5th Mediterranean Congress of Chemotherapy; October, 1986; Cairo, Egypt.

112 Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A2

Injections. Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.

113 Hendry, L.B., Lehner, A.F., Muldoon, T.G., Copland, J.A., Mahesh, V.B., Mills, T.M., Burzynski, S.R. Investigations of the Mode of Action of Antineoplaston A10: Evidence for Binding to DNA. Presented at the 14th International Cancer Congress; August, 1986; Budapest, Hungary.

114 Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Antineoplaston A5 Injections. Presented at the III World Conference on Clinical Pharmacology and Therapeutics; July, 1986; Stockholm, Sweden.

115 Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A3

Injections. Presented at the 7th International Symposium on Future Trends in

Chemotherapy; May, 1986; Pisa, Italy.

116 Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as Novel Cancer Chemotherapeutic Agents. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

117 Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In Vitro Cancer Growth Iinhibition and Acute Animal Toxicity Studies of Antineoplaston A3. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

118 Lehner, A.F., Copland, J.A., Muldoon, T.G., Burzynski, S.R., Hendry, L.B. In Vitro Studies of the Stereospecificity of Antineoplaston A10 Interaction with Double-stranded DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 29 of 43

119 Ashraf, A.Q., Kampalath, B.N., Liau, M.C., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston A10 Following Oral Administration in Rats. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

120 Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F.

Stereochemical Modeling Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

121 Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston Al 0

Injections. Presented at the 2nd Biennial Conference of Indian Society of

Oncology; February, 1986; Bombay, India.

122 Burzynski, S.R., Lehner, A.F., Hendry, L.B. Putative Mechanism of Action of a Novel Peptide Analog with Apparent Antineoplastic Activity: Stereospecific interaction with DNA. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.

123 Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative Assay of Plasma and Urinary Peptides as Aid for Evaluation of Cancer Patients Undergoing Antineoplaston Therapy. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.

124 Hendry, L.B. Lehner, A.F., Burzynski, S.R. A Novel Naturally-occurring Peptide

Analog with Apparent Antineoplastic Activity May Interact with DNA. Presented at the International Symposium, Cancer: Perspective for Control; August, 1985; Beijing, China.

125 Hendry, L.B., Lehner, A.F., Burzynski, S.R. Spectroscopic Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 12th Symposium of the International Association for Comparative Research on Leukemia and Related Disease; July, 1985; Hamburg, Germany.

126 Burzynski, S.R. Phase I Clinical Studies of Antineoplaston AS2-5 Iinjections.

Presented at the 14th International Congress of Chemotherapy; June, 1985; Kyoto, Japan.

127 Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Phase I Clinical Studies of Antineoplaston AS2-1 Injection. Presented at the 3rd European Conference on Clinical Oncology and Cancer Nursing; June, 1985; Stockholm, Sweden.

128 Liau, M.C., Burzynski, S.R. Alteration of Methylation Complex of Isoenzymes Critical to Malignant Evolution. Presented at the 12th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, October,

1984; Houston, USA.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 30 of 43

129 Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology Studies of Oral Formulation of Antineoplaston A10 in Cancer Patients. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.

130 Lee, S. S., Mohabbat, M.O., Burzynski, S.R. Tissue Culture and Animal Toxicity Studies of Antineoplaston A2. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.

131 Burzynski, S.R., Hendry, L.B., Mohabbat, M.O., Liau, M.C., Khalid, M., Burzynski, B. Purification, Structure Determination, Synthesis and Animal Toxicity Studies of Antineoplaston A10; PS 12.4.11-4. Presented at the 13th International Congress on Chemotherapy, TOM 17; August, 1983; Vienna, Austria.

132 Burzynski, S.R. Recent Advances in Ultramicroanalysis of Biologically Active Peptides. Presented at the 30th Southwest Regional American Chemical Society meeting, 1974; Houston, Texas.

133 Ungar, G., Burzynski, S.R. Detection of a Behavior-inducing Peptide

(Scotophobin) in Brain by Ultramicroanalytical Method. Fed Proc., 1972; 31:

398.

134 Burzynski, S.R., Czerniak, Z. The Photometry of Negative Printed Chromatograms and its Application for Amino Acid Analysis in Human Blood. Biuletyn VII Ogolnopolskiej Konferencji Studenckich Kol Naukowych Akademii Medycznych; 1966; Poznan, Poland.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 31 of 43

***PATENTS/专利***

***Patent No. National Country Title***

专利号 ***Patent No.*** 国家标题

|  |  |  |  |
| --- | --- | --- | --- |
|  | 国家专利号 |  | |
| ***AIDS*** |  |
| **638869** |  | Australia | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** | ATE135,217 | Austria | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Belgium | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Denmark | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Europe | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | France | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** | 69117923 | Germany | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** | 3019970 | Greece | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Italy | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Luxembourg | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Netherlands | Pharmaceutical compositions for use in treating AIDS. |
| **28633** |  | Philippines | Methods for treating AIDS. |
| **81889** |  | Singapore | Pharmaceutical compositions for use in treating AIDS. |
| **91/6977** |  | South Africa | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Spain | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Sweden | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | Switzerland | Pharmaceutical compositions for use in treating AIDS. |
| **0500905** |  | United Kingdom | Pharmaceutical compositions for use in treating AIDS. |
| **5089508** |  | USA | Methods for treating AIDS. |
| **5254587** |  | USA | Methods for treating AIDS. |

***Aminocare***

Arab Emirates Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

**2002352843** Australia Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Brazil Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

**ZL02823606.8** China Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 32 of 43

***Patent No. National Country Title***

***Patent No.***

|  |  |  |
| --- | --- | --- |
| **009516** | Eurasia | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. |
|  |  | The Eurasian patent has been validated in the following contracting  countries: Armenia (AM), Azerbaijan (AZ), Belarus (BY), Kazahstan (KZ), Kirgizstan (KG), Moldava (MD), Russia (RU), Tajikistan (TJ) and |
|  |  | Turkmenistan (TM). |
| **1450781** | Europe | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **DE60212393T2** | Germany | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
|  | Hungary | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **212246** | India | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **ID0018257** | Indonesia | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **162141** | Israel | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **247856** | Mexico | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **532833** | New Zealand | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
|  | Norway | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **1-2004-500758** | Philippines | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **953483** | Republic of Korea | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **121173** | Romania | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **104603** | Singapore | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **21542** | Slovenia | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **2004/4115** | South Africa | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **78977** | Ukraine | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |
| **7427619132** | USA | Formulation of amino acids and riboflavin useful to reduce toxic effects of |
|  |  | cytotoxic chemotherapy. |

***Atherosclerosis and Restenosis***

|  |  |  |
| --- | --- | --- |
| **757114** | Australia | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. |
| **2345409** | Canada | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 33 of 43

***Patent No. National Country Title***

***Patent No.***

**1171110** Europe Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

**69916330T2** Germany Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

**1045253** Hong Kong Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

**2219102** Spain Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

**6127419** USA Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

***Autoimmune disease***

**656484** Australia Compositions and methods for treating autoimmune diseases.

|  |  |  |  |
| --- | --- | --- | --- |
| **0603383** | E162,714 | Austria | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Belgium | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Denmark | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Europe | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | France | Compositions and methods for treating autoimmune diseases. |
| **0603383** | 69316729.7 | Germany | Compositions and methods for treating autoimmune diseases. |
| **0603383** | 980400879 | Greece | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Ireland | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Italy | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Luxembourg | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Monaco | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Netherlands | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Portugal | Compositions and methods for treating autoimmune diseases. |
| **81891** |  | Singapore | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Spain | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Sweden | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | Switzerland | Compositions and methods for treating autoimmune diseases. |
| **0603383** |  | United Kingdom | Compositions and methods for treating autoimmune diseases. |
| **5646182** |  | USA | Methods for treating autoimmune diseases. |
| ***Hypercholesterolemia*** | | | |
| **1206936** |  | Europe | Phenylacetic acid compositions for treating or preventing hypercholesterolemia. |
| **1206936** | 60112872T2 | Germany | Phenylacetic acid compositions for treating or preventing hypercholesterolemia. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 34 of 43

***Patent No. National Country Title***

***Patent No.***

**1048588** Hong Kong Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

**6,987,131** USA Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

***Liposomal Therapies***

**2254772** Canada Liposomal Antineoplastons Therapies with Markedly Improved

Antineoplastic Activity.

|  |  |  |  |
| --- | --- | --- | --- |
| **0906088** |  | Europe | Liposomal Antineoplastons Therapies with Markedly Improved  Antineoplastic Activity. |
| **0906088** |  | France | Liposomal Antineoplastons Therapies with Markedly Improved  Antineoplastic Activity. |
| **0906088** | 69734713.3-  08 | Germany | Liposomal Antineoplastons Therapies with Markedly Improved  Antineoplastic Activity. |
| **4320052** |  | Japan | Liposomal Antineoplastons Therapies with Markedly Improved  Antineoplastic Activity. |
| **6013278** |  | USA | Liposomal Antineoplastons Therapies with Markedly Improved  Antineoplastic Activity. |

***Methods for preparing 3-(N-phenylacetylamino) piperidine-2,6-dion.***

|  |  |  |
| --- | --- | --- |
| **92391** | Finland | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **1562** | Kazakhstan | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **5474** | Latvia | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **3518** | Lithuania | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **26099** | Philippines | Methods for preparing 3-(N-phenylacetyl-aminopiperidine)-2,6-dion. |
| **163552** | Poland | Methods for preparing 3-(N-phenylacetylamino) piperidine-2,6-dion. |
| **139204** | Republic of Korea | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **1809830** | Russia | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **42331** | Taiwan | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **15756** | Ukraine | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| **4918193** | USA | Methods for preparing 3-(N-phenylacetylamino-piperidine)-2,6-dion. |
| ***Neoplastic disease / Purified*** | | |
| **551109** | Australia | Purified antineoplaston fractions and methods of treating neoplastic |
|  |  | disease. |
| **1188218** | Canada | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **162813** | Denmark | Purified antineoplaston fractions and methods of treating neoplastic |
|  |  | disease. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 35 of 43

|  |  |  |
| --- | --- | --- |
| ***Patent No. National***  ***Patent No.***  **302/1989** | ***Country***  Hong Kong | ***Title***  Purified antineoplaston fractions and methods of treating neoplastic |
|  |  | disease. |
| **65960** | Israel | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **2010265** | Japan | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **2010676** | Japan | Purified antineoplaston fractions. |
| **2057285** | Japan | Pharmaceutical compositions for neoplastic disease. |
| **MY102918A** | Malaysia | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **200805** | New Zealand | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **163595** | Norway | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **82/4178** | South Africa | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **512894** | Spain | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **4470970** | USA | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **4558057** | USA | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| **4559325** | USA | Purified antineoplaston fractions and methods of treating neoplastic disease. |
| ***Neurofibromatosis*** |  |  |
| **683145** | Australia | Methods for treating neurofibromatosis. |
| **0680756** E183,390 | Austria | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** | Belgium | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** | Denmark | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** | Europe | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** | France | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** 69511453.0 | Germany | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** | Greece | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **1016408** | Hong Kong | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 36 of 43

***Patent No. National Country Title***

***Patent No.***

|  |  |  |  |
| --- | --- | --- | --- |
| **0680756** |  | Ireland | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** | 26583/BE/9 | Italy | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Lithuania | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Luxembourg | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Monaco | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Netherlands | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Portugal | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Slovenia | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **95/3500** |  | South Africa | Methods for treating neurofibromatosis. |
| **0680756** |  | Spain | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Sweden | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | Switzerland | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **0680756** |  | United Kingdom | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis. |
| **5391575** |  | USA | Methods for treating neurofibromatosis. |

***Parkinson's disease***

**642045** Australia Pharmaceutical compositions for use in treating Parkinson's disease.

|  |  |  |  |
| --- | --- | --- | --- |
| **0500901** |  | Austria | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** |  | Belgium | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** |  | Denmark | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** |  | Europe | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** |  | France | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | 69114261.0 | Germany | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | 3018437 | Greece | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | 19057/BE/96 | Italy | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** |  | Luxembourg | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** |  | Netherlands | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **28523** |  | Philippines | Methods for treating Parkinson's disease. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 37 of 43

***Patent No. National Country Title***

***Patent No.***

|  |  |  |
| --- | --- | --- |
| **91/7016** | South Africa | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | Spain | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | Sweden | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | Switzerland | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **0500901** | United Kingdom | Pharmaceutical compositions for use in treating Parkinson's disease. |
| **5116622** | USA | Methods for treating Parkinson's disease. |

***Pharmaceutical composition comprising phenyl acetyl glutamine ect.***

|  |  |  |  |
| --- | --- | --- | --- |
| **0069232** | E23113 | Austria | Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3- |
|  |  |  | (phenylacetylamino) piperidine-2, 6-dione, a process for isolating thelatter  from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |
| **0069232** |  | Belgium | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  |  | combination of this compound with phenylacetic acid or 3-  (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) |
|  |  |  | piperidine-2, 6-dione. |
| **1262907** |  | Canada | Purified antineoplaston fractions and methods of treating neoplastic |
|  |  |  | disease. |
| **0069232** |  | Europe | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  |  | combination of this compound with phenylacetic acid or 3- |
|  |  |  | (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter  from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |
| **0069232** |  | France | Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3- (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter |
|  |  |  | from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |
| **0069232** | P3273952.4 | Germany | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  |  | combination of this compound with phenylacetic acid or 3- |
|  |  |  | (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter  from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |
| **0069232** | 22434/BE/86 | Italy | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  |  | combination of this compound with phenylacetic acid or 3-  (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) |
|  |  |  | piperidine-2, 6-dione. |
| **0069232** |  | Luxembourg | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  |  | combination of this compound with phenylacetic acid or 3-  (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter |
|  |  |  | from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |
| **0069232** |  | Netherlands | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  |  | combination of this compound with phenylacetic acid or 3- |
|  |  |  | (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter  from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 38 of 43

***Patent No. National Country Title***

***Patent No.***

**0069232** Sweden Pharmaceutical composition comprising phenylacetylglutamine, a

|  |  |  |
| --- | --- | --- |
|  | | combination of this compound with phenylacetic acid or 3- (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) |
| piperidine-2, 6-dione. |
| **0069232** | Switzerland | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  | combination of this compound with phenylacetic acid or 3-  (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter |
|  |  | from urine and a process for the synthesis of 3-(phenylacetylamino)  piperidine-2, 6-dione. |
| **0069232** | United Kingdom | Pharmaceutical composition comprising phenylacetylglutamine, a |
|  |  | combination of this compound with phenylacetic acid or 3-  (phenylacetylamino) piperidine-2, 6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino) |
|  |  | piperidine-2, 6-dione. |
| ***Skin*** |  |  |
| **0197358** | Austria | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | Belgium | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **1262866** | Canada | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin |
|  |  | wrinkles and hyperpigmentation. |
| **0197358** | Europe | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | France | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | Germany | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | Italy | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **1953215** | Japan | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | Luxembourg | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | Netherlands | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin. |
| **0197358** | Sweden | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | Switzerland | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **0197358** | United Kingdom | Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of |
|  |  | skin. |
| **4593038** | USA | Topical use of 3-phenylacetylamino-2, 6-piperidinedione for treatment of |
|  |  | skin wrinkles and hyperpigmentation. |

***Synthesis of 4-phenylbutyric acid.***

**2447803** Canada Synthesis of 4-phenylbutyric acid.

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 39 of 43

***Patent No. National Country Title***

***Patent No.***

|  |  |  |
| --- | --- | --- |
| **ZL02810264.9** | China | Synthesis of 4-phenylbutyric acid. |
| **1065996** | Hong Kong | Synthesis of 4-phenylbutyric acid. |
| **229199** | India | Synthesis of 4-phenylbutyric acid. |
| **4338401** | Japan | Synthesis of 4-phenylbutyric acid. |
| **201802** | Poland | Synthesis of 4-phenylbutyric acid. |
| **10-0905139** | Republic of Korea | Synthesis of 4-phenylbutyric acid. |
| **2297998** | Russia | Synthesis of 4-phenylbutyric acid. |
| **0101088** | Singapore | Synthesis of 4-phenylbutyric acid. |
| **6372938 B1** | USA | Synthesis of 4-phenylbutyric acid. |

***Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy.***

**4444890** USA Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy.

***Toothpaste***

**7087219** USA Toothpaste Containing Anticancer Agents.

***Treatment of Neoplastic Disease***

**ZL200410061600.5** China A composition for treating neoplastic disease and the use thereof.

|  |  |  |  |
| --- | --- | --- | --- |
| **1098643** |  | Europe | Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease. |
| **1098643** |  | France | Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for |
|  |  |  | the treatment of neoplastic disease. |
| **1098643** | 69914084.6- | Germany | Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for |
|  | 08 |  | the treatment of neoplastic disease. |
| **227008** |  | India | A Phamaceutical Composition Comprising Phenylacetylglutamine, |
|  |  |  | Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of |
|  |  |  | Neoplastic Disease. |
| **0414587** |  | Republic of Korea | A Phamaceutical Composition Comprising Phenylacetate and |
|  |  |  | Phenylacetylglutamine. |
| **0417100** |  | Republic of Korea | A Phamaceutical Composition Comprising Phenylacetate and |
|  |  |  | Phenylacetylisoglutamine. |
| **0417101** |  | Republic of Korea | A Pharmaceutical Composition Comprising an Aqueous Solution of |
|  |  |  | Phenylacetate. |
| ***Treatment Regimen*** | |  |  |
| **759278** | | Australia | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** | | Belgium | Treatment regimen for administration of phenylacetylglutamine, |
|  | |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **2336945** | | Canada | Treatment regimen for administration of phenylacetylglutamine, |
|  | |  | phenylacetylisoglutamine, and/or phenylacetate. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 40 of 43

***Patent No. National Country Title***

***Patent No.***

**ZL99811314.X** China Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.

|  |  |  |  |
| --- | --- | --- | --- |
| **1098643** |  | Denmark | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. |
| **004179** |  | Eurasia | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
|  |  |  | The Eurasian patent has been validated in the following contracting countries: Azerbajian, Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova |
|  |  |  | and The Russian Federation. |
| **1098643** |  | Greece | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **01107897.8** |  | Hong Kong | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **ID0012068** |  | Indonesia | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **ID0013227** |  | Indonesia | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **140848** |  | Israel | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Italy | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Latvia | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Luxembourg | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **222968** |  | Mexico | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Netherlands | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **509244** |  | New Zealand | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Portugal | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **399658** |  | Republic of Korea | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **78643** |  | Singapore | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **2001/0622** |  | South Africa | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** | 2214866 | Spain | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Sweden | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **1098643** |  | Switzerland | Treatment regimen for administration of phenylacetylglutamine, |
|  |  |  | phenylacetylisoglutamine, and/or phenylacetate. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 41 of 43

|  |  |  |
| --- | --- | --- |
| ***Patent No. National***  ***Patent No.***  **1098643** | ***Country***  United Kingdom | ***Title***  Treatment regimen for administration of phenylacetylglutamine, |
|  |  | phenylacetylisoglutamine, and/or phenylacetate. |
| **6258849** | USA | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. |
| **6943192B2** | USA | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. |
| ***VHL*** |  |  |
| **012908** | Eurasia | Method for treatment of Von Hippel-Lindau (VHL) disease with phenylacetyl- derivatives. |
|  |  | The Eurasian patent has been validated in the following contracting countries: Russia (RU). |
| **1855665** | Europe | Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease. |
| ***Viral infections*** |  |  |
| **0601164** | Austria | Methods for treating viral infections. |

|  |  |  |  |
| --- | --- | --- | --- |
| **0601164** |  | Belgium | Methods for treating viral infections. |
| **0601164** |  | Denmark | Methods for treating viral infections. |
| **0601164** |  | Europe | Methods for treating viral infections. |
| **0601164** |  | France | Methods for treating viral infections. |
| **0601164** | 69327642.8 | Germany | Methods for treating viral infections. |
| **0601164** |  | Greece | Methods for treating viral infections. |
| **0601164** |  | Ireland | Methods for treating viral infections. |
| **0601164** |  | Italy | Methods for treating viral infections. |
| **0601164** |  | Luxembourg | Methods for treating viral infections. |
| **0601164** |  | Monaco | Methods for treating viral infections. |
| **0601164** |  | Netherlands | Methods for treating viral infections. |
| **0601164** |  | Portugal | Methods for treating viral infections. |
| **67344** |  | Singapore | Methods for treating viral infections. |
| **0601164** |  | Spain | Methods for treating viral infections. |
| **0601164** |  | Sweden | Methods for treating viral infections. |
| **0601164** |  | Switzerland | Methods for treating viral infections. |
| **0601164** |  | United Kingdom | Methods for treating viral infections. |
| **5244922** |  | USA | Methods for treating viral infections. |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 42 of 43

***Trade Name/商品名称***

***Tradename No. Country Title***

**Reg.No.: CDN-HY-** China China Domain Name Registration Certificate. Internet Keyword:

**07011055; (56); (57).** aminocare. Valid until: 5/23/2017

China Domain Name Registration Certificate. Internet Keyword:

aminocare.cn. Valid until: 5/23/2012

China Domain Name Registration Certificate. Internet Keyword: Aminocare.com.cn. Valid until: 5/23/2012

***Trademarks/商标***

***Trademark No. Country/State Title***

**ZC4695730SL** China Aminocare (PENDING)

**004006102** Europe Fengenal in Class 5

**004006334** Europe Avavital

**004006359** Europe Bugenal in Class 5

**004006375** Europe Lubgen Farma in Classes 39 (distribution of pharmacutical preparation) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)

**004006425** Europe Cengenal in Class 5

**004006664** Europe Astugenal in Class 5

**004006979** Europe Atengenal in Class 5

**300343377** Hong Kong Aminocare in Class 5

**188750** Poland Lubgen Farma

**120234** Republic of Korea Lubgen Farma in Class 35 (Arranging of pharmaceuticals sales)

**129501** Republic of Korea Lubgen Farma in Class 40 (custom manufacturing of pharmaceutical preparations for others)

**620203** Republic of Korea Bugenal in Class 5

**622094** Republic of Korea Astugenal in Class 5

**622095** Republic of Korea Atengenal in Class 5

**622096** Republic of Korea Avavital in Class 5

**622097** Republic of Korea Cengenal in Class 5

**622098** Republic of Korea Fengenal in Class 5

**292206** Russia Astugenal in Class 5

**293368** Russia Bugenal in Class 5

**300114** Russia Cengenal in Class 5

**304514** Russia Lubgen Farma in Class 35 (Arranging of pharmaceuticals sales) and in

Class 40 (custom manufacturing of pharmaceutical preparations for others)

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10

Stanislaw R. Burzynski, M.D., Ph.D. – Page 43 of 43

***Trademark No. Country Title***

|  |  |  |
| --- | --- | --- |
| **304679** | Russia | Avavital in Class 5 |
| **304680** | Russia | Atengenal in Class 5 |
| **304681** | Russia | Fengenal in Class 5 |
| **327323** | Russia | Aminocare in Class 5 |
| **01165897** | Taiwan | Aminocare in Class 5 |
| **050590** | USA | State Trademark ‘Antineoplaston’, Texas |
| **1719793** | USA | Federal trademark 'Antineoplaston' for pharmaceuticals. |
| **2999213** | USA | Bugenal in Class 5 |
| **3142996** | USA | Ampolgen Pharmaceuticals, LLC. In Classes 35 and 42. |
| **3160376** | USA | Aminocare in Class 6 |
| **3169436** | USA | Avavital in Class 5 |
| **3174860** | USA | Fengenal in Class 5 |
| **3177785** | USA | Astugenal in Class 5 |
| **318432** | USA | Atengenal in Class 5 |
| **3276180** | USA | Cengenal in Class 5 |

REV: 07/02/08, 08/08/08, 08/18/08, 09/30/08, 10/06/08, 10/22/08, 11/24/08, 12/17/08, 02/25/09, 04/02/09, 04/29/09, 07/30/09, 01/11/10, 07/09/10